Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers

A targeted therapy is recommended in case of ERBB2 alteration for breast and gastric carcinomas, but miscellaneous other tumor types are ERBB2-altered at low prevalence. Broadening the administration of HER2 inhibitors across tumor types and genomic alterations could benefit to patients with refract...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Cabel, Luc, Fuerea, Alina, Lacroix, Ludovic, Baldini, Capucine, Martin, Patricia, Hollebecque, Antoine, Postel-Vinay, Sophie, Varga, Andrea, Balheda, Rastilav, Gazzah, Anas, Michot, Jean-Marie, Marabelle, Aurélien, Rouleau, Etienne, Solary, Eric, De Baere, Thierry, Angevin, Eric, Armand, Jean-Pierre, Michiels, Stefan, Scoazec, Jean Yves, Ammari, Samy, André, Fabrice, Soria, Jean-Charles, Massard, Christophe, Verlingue, Loic
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2018
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5839398/
https://ncbi.nlm.nih.gov/pubmed/29515767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24188
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak